Navigation Links
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Date:7/8/2008

unique mechanism of action as a non-chain terminating nucleoside analog HBV polymerase inhibitor may demonstrate additive antiviral benefit in combination with tenofovir's recently demonstrated antiviral potency in HBV," stated Dr. Michelle Berrey, Pharmasset's Chief Medical Officer. "We also plan to reproduce the results from earlier studies demonstrating clevudine's ability to provide a sustained virologic response in patients with eAg negative chronic HBV infection, as either monotherapy or in combination, offering infected individuals and their physicians an important new treatment option."

Ongoing Registration Studies for New Drug Application (NDA)

The ongoing clevudine Phase 3 registration program includes two 48-week clinical trials designed to demonstrate the superiority of clevudine 30mg over Hepsera(R) (adefovir dipivoxil) 10mg, each administered once-daily as monotherapy. Pharmasset plans to submit the 48-week data from these studies to the FDA as the basis for the clevudine marketing approval. Please see http://www.clinicaltrials.gov or e-mail clinicaltrials@pharmasset.com for more information about the clevudine registration studies.

South Korean Registration Studies for Clevudine

Bukwang received marketing approval for clevudine from the South Korean FDA based on two 24-week, placebo-controlled, double-blind, randomized, multi-center South Korean Phase 3 registration trials in 337 patients. Study 301 enrolled 248 HBeAg+ patients who received clevudine 30 mg or a placebo once-daily, and Study 302 enrolled 89 HBeAg- patients who received clevudine 30 mg or a placebo once-daily. All patients were evaluated for an additional 24 weeks of follow-up care without clevudine treatment.

At 24 weeks on treatment with clevudine, 59% of HBeAg+ patients achieved undetectable HBV DNA and 92% of HBeAg- patients achieved undetec
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Receives Notice of Allowance
2. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
3. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
4. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
5. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
8. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
9. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
10. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014  Veran Medical Technologies, a ... the positive, cost-effective final results for the ... The SPiNPerc endobronchial percutaneous biopsy study results ... to biopsy when a traditional bronchoscopic method ... experience positive financial outcomes when more can ...
(Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... N.C., Jan. 19, 2011 As Pisgah Laboratories, Inc. ... it will soon begin scale-up of its patent-pending form ... of hydrocodone which imparts abuse deterrent properties to a ... clinical trials in their FDA / DEA registered facility. ...
... Medical Group Inc. (Nasdaq: WWIN ), ("Winner ... medical disposables and non-woven fabric made from 100% natural ... will participate in Arab Health 2011, to be held ... Exhibition Centre in Dubai, UAE. During ...
Cached Medicine Technology:Abuse Deterrent Hydrocodone / Acetaminophen Leads NDA Pipeline 2Abuse Deterrent Hydrocodone / Acetaminophen Leads NDA Pipeline 3Winner Medical to Participate in Arab Health 2011, International Healthcare Exhibition, in Dubai 2Winner Medical to Participate in Arab Health 2011, International Healthcare Exhibition, in Dubai 3
(Date:7/11/2014)... H.E.A.R Me Out Listens to Needs of ... to provide comprehensive information and services available to Colorado’s ... Coloradoans with hearing loss, this organization is the first ... the local and state resources that aims to give ... H.E.A.R. Me Out and its website was founded by ...
(Date:7/11/2014)... Having experienced mental illness from the perspectives ... hospital staff, Roger Grainger gives readers an intimate look at ... book, “You Never Get Out.” , According to the Mental ... will experience some kind of mental health problem in the ... take a look at the way mental illness is addressed ...
(Date:7/11/2014)... of personalized medicine may be just around the corner, ... Min Yu and scientists at Massachusetts General Hospital and ... in Science , Yu and her colleagues report ... blood streams of six patients. Some of these deadly ... to and establish secondary tumors in vital organs such ...
(Date:7/11/2014)... July 11, 2014 Cancer researchers in ... a significant impact on how patients respond to treatment ... mesothelioma. Surviving Mesothelioma has the full story. Click ... Researchers at the University of Ljubljana and the Ljubljana ... for different types of polymorphisms. They found that ...
(Date:7/11/2014)... Re-tearing a repaired knee Anterior Cruciate Ligament (ACL) ... presented today at the American Orthopaedic Society for Sports ... and patient education regarding modifiable risk factors may minimize ... “Our research suggests that a few risk factors such ... may point to the possibility of re-injury,” said lead ...
Breaking Medicine News(10 mins):Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 2Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 3Health News:Psychiatric Hospital Patient and Registered Psychologist Explores Mental Health and Therapy in New Book "You Never Get Out" 2Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:New Study May Identify Risk Factors for ACL Re-injury 2
... general practitioners , who were free of dementia ... years and 3 years later by means of ... alcohol consumption and DSM-IV dementia diagnoses. Associations between ... alcohol (wine, beer, mixed alcohol beverages) and incident ...
... 7, 2011 Elsevier, the leading global publisher ... announced today it has begun offering Arabic bilingual editions ... the Middle East. The first order was recently received ... one of Elsevier,s many meant to help improve the ...
... , The U.S. spends around 2 billion dollars a ... large portion of this used for groundwater monitoring. Yet ... University,s Biodesign Institute, the information gathered is often of ... grant from the U.S. Department of Defense, Halden, assistant ...
... The 2011 Sleep in America poll released today by the National ... hour before bed. It also finds that a significant number of ... searching for ways to cope. , Many Americans report dissatisfaction ... 43% of Americans between the ages of 13 and 64 say ...
... heart disease, involving scientists from the University of ... of heart attacks. Professor Nilesh Samani, British ... Leicester, based at Glenfield Hospital, who co-led the international ... genes identified were not previously known to be involved ...
... Creating a healthy eating action plan and visualizing yourself carrying ... suggest. "Telling people to just change the way they ... study author Barbel Knauper, an associate professor of psychology at ... "But research has shown that if people make a ...
Cached Medicine News:Health News:Alcohol consumption after age 75 associated with lower risk of developing dementia 2Health News:Alcohol consumption after age 75 associated with lower risk of developing dementia 3Health News:Alcohol consumption after age 75 associated with lower risk of developing dementia 4Health News:Monitoring waste in groundwater (without all the waste) 2Health News:Sleepy connected Americans 2Health News:Sleepy connected Americans 3Health News:Sleepy connected Americans 4Health News:Sleepy connected Americans 5Health News:Sleepy connected Americans 6Health News:Leicester leads on heart attack genetic link discovery 2
... Merlin is a superior full-color, auto-focus, desktop ... user in mind, Merlin enables the user ... and white, high contrast positive or high ... magnifier, this optional feature enables the user ...
... general purpose incubators designed to ... and uniformity required for the ... versatile microprocessor controlled incubators feature ... easy-to-read digital display, and built-in ...
... Economy Incubators available in five different models. ... 1.4 cu. Ft. (39 liters), 2.5 cu. ... (129 liters. Equally important, Precision Economy Incubators ... temperature sensitivity, stability, and uniformity. As a ...
Aspheric diagnostic lens. 90D...
Medicine Products: